NO310231B1 - Sulfonamid-inhibitorer av matriks-metalloproteinaser, anvendelse av disse og farmasöytiske preparater inneholdende dem - Google Patents

Sulfonamid-inhibitorer av matriks-metalloproteinaser, anvendelse av disse og farmasöytiske preparater inneholdende dem Download PDF

Info

Publication number: NO310231B1
Authority: NO; Norway
Prior art keywords: phenyl; benzenesulfonylamino; piperidin; compound according; propionic acid
Prior art date: 1995-11-17

Application number

NO19982223A

Other languages

English (en)

Norwegian (no)

Other versions

NO982223L (no

NO982223D0 (no

Inventor

Daniel Fred Ortwine

Jr Claude Forsey Purchase

Andrew David White

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-17

Filing date

1998-05-15

Publication date

2001-06-11

1998-05-15 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1998-05-15 Publication of NO982223L publication Critical patent/NO982223L/no

1998-05-15 Publication of NO982223D0 publication Critical patent/NO982223D0/no

2001-06-11 Publication of NO310231B1 publication Critical patent/NO310231B1/no

Links

102000002274 Matrix Metalloproteinases Human genes 0.000 title claims abstract description 25
108010000684 Matrix Metalloproteinases Proteins 0.000 title claims abstract description 25
239000000825 pharmaceutical preparation Substances 0.000 title claims description 18
239000003112 inhibitor Substances 0.000 title abstract description 12
150000003456 sulfonamides Chemical class 0.000 title description 19
229940124530 sulfonamide Drugs 0.000 title description 14
150000001875 compounds Chemical class 0.000 claims abstract description 106
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 claims abstract description 19
102000000424 Matrix Metalloproteinase 2 Human genes 0.000 claims abstract description 17
108010016165 Matrix Metalloproteinase 2 Proteins 0.000 claims abstract description 17
108010016160 Matrix Metalloproteinase 3 Proteins 0.000 claims abstract description 13
206010028980 Neoplasm Diseases 0.000 claims abstract description 13
208000037260 Atherosclerotic Plaque Diseases 0.000 claims abstract description 12
201000011510 cancer Diseases 0.000 claims abstract description 11
208000025865 Ulcer Diseases 0.000 claims abstract description 8
206010003246 arthritis Diseases 0.000 claims abstract description 8
230000001684 chronic effect Effects 0.000 claims abstract description 8
201000006417 multiple sclerosis Diseases 0.000 claims abstract description 8
231100000397 ulcer Toxicity 0.000 claims abstract description 8
208000023275 Autoimmune disease Diseases 0.000 claims abstract description 7
206010052428 Wound Diseases 0.000 claims abstract description 7
208000027418 Wounds and injury Diseases 0.000 claims abstract description 7
230000001363 autoimmune Effects 0.000 claims abstract description 7
208000027866 inflammatory disease Diseases 0.000 claims abstract description 7
230000009545 invasion Effects 0.000 claims abstract description 7
210000000265 leukocyte Anatomy 0.000 claims abstract description 7
208000037803 restenosis Diseases 0.000 claims abstract description 7
208000028169 periodontal disease Diseases 0.000 claims abstract description 6
-1 (R)-3-(1H-indol-3-yl)-2-[4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-propionic acid disodium salt monohydrate Chemical compound 0.000 claims description 46
150000003839 salts Chemical class 0.000 claims description 32
229910052739 hydrogen Inorganic materials 0.000 claims description 30
239000001257 hydrogen Substances 0.000 claims description 27
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
238000002360 preparation method Methods 0.000 claims description 17
150000002431 hydrogen Chemical group 0.000 claims description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 9
208000007474 aortic aneurysm Diseases 0.000 claims description 7
208000004210 Pressure Ulcer Diseases 0.000 claims description 5
ZQXYDSXOIXNPBN-RUZDIDTESA-N (2r)-3-phenyl-2-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]propanoic acid Chemical compound C([C@H](C(=O)O)NS(=O)(=O)C=1C=CC(=CC=1)N1CCC(CC1)C=1C=CC=CC=1)C1=CC=CC=C1 ZQXYDSXOIXNPBN-RUZDIDTESA-N 0.000 claims description 4
HEABEIGWLYMIBY-JOCHJYFZSA-N (2r)-4-methyl-2-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]pentanoic acid Chemical compound C1=CC(S(=O)(=O)N[C@H](CC(C)C)C(O)=O)=CC=C1N1CCC(C=2C=CC=CC=2)CC1 HEABEIGWLYMIBY-JOCHJYFZSA-N 0.000 claims description 4
ULOTXPTWJAUGGE-MHZLTWQESA-N (2s)-3-(1h-indol-3-yl)-2-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)S(=O)(=O)C(C=C1)=CC=C1N(CC1)CCC1C1=CC=CC=C1 ULOTXPTWJAUGGE-MHZLTWQESA-N 0.000 claims description 4
ZQXYDSXOIXNPBN-VWLOTQADSA-N (2s)-3-phenyl-2-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]propanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=CC(=CC=1)N1CCC(CC1)C=1C=CC=CC=1)C1=CC=CC=C1 ZQXYDSXOIXNPBN-VWLOTQADSA-N 0.000 claims description 4
HEABEIGWLYMIBY-QFIPXVFZSA-N (2s)-4-methyl-2-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]pentanoic acid Chemical compound C1=CC(S(=O)(=O)N[C@@H](CC(C)C)C(O)=O)=CC=C1N1CCC(C=2C=CC=CC=2)CC1 HEABEIGWLYMIBY-QFIPXVFZSA-N 0.000 claims description 4
WKLSCPMFMSEKHJ-VWLOTQADSA-N (2s)-2-[[4-[4-(3-methoxyphenyl)piperazin-1-yl]phenyl]sulfonylamino]-3-phenylpropanoic acid Chemical compound COC1=CC=CC(N2CCN(CC2)C=2C=CC(=CC=2)S(=O)(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)=C1 WKLSCPMFMSEKHJ-VWLOTQADSA-N 0.000 claims description 3
IPPBZBAQYUONQO-YTTGMZPUSA-N (2s)-3-(4-phenylmethoxyphenyl)-2-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]propanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=CC(=CC=1)N1CCC(CC1)C=1C=CC=CC=1)C(C=C1)=CC=C1OCC1=CC=CC=C1 IPPBZBAQYUONQO-YTTGMZPUSA-N 0.000 claims description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
GNSLACGSDSJAIQ-UHFFFAOYSA-N [4-(4-phenyl-piperidin-1-yl)-benzenesulfonylamino]-acetic acid Chemical group C1=CC(S(=O)(=O)NCC(=O)O)=CC=C1N1CCC(C=2C=CC=CC=2)CC1 GNSLACGSDSJAIQ-UHFFFAOYSA-N 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
DIMHQAITVXMHMQ-SANMLTNESA-N (2s)-2-[[4-(4-benzylpiperidin-1-yl)phenyl]sulfonylamino]-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=CC(=CC=1)N1CCC(CC=2C=CC=CC=2)CC1)C1=CC=CC=C1 DIMHQAITVXMHMQ-SANMLTNESA-N 0.000 claims description 2
PNCLRHJDVNOKGF-DEOSSOPVSA-N (2s)-2-[[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]sulfonylamino]-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=CC(=CC=1)N1CCN(CC1)C=1C=CC(O)=CC=1)C1=CC=CC=C1 PNCLRHJDVNOKGF-DEOSSOPVSA-N 0.000 claims description 2
NSACXBTYAXSYCE-VWLOTQADSA-N (2s)-3-(4-hydroxyphenyl)-2-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]propanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=CC(=CC=1)N1CCC(CC1)C=1C=CC=CC=1)C1=CC=C(O)C=C1 NSACXBTYAXSYCE-VWLOTQADSA-N 0.000 claims description 2
UBSXVJZNZIPKCM-DEOSSOPVSA-N (2s)-3-phenyl-2-[[4-(4-phenylpiperazin-1-yl)phenyl]sulfonylamino]propanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=CC(=CC=1)N1CCN(CC1)C=1C=CC=CC=1)C1=CC=CC=C1 UBSXVJZNZIPKCM-DEOSSOPVSA-N 0.000 claims description 2
UXRQPYBOLVQYQD-UHFFFAOYSA-N 2-[2-methylpropyl-[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]acetic acid Chemical compound C1=CC(S(=O)(=O)N(CC(O)=O)CC(C)C)=CC=C1N1CCC(C=2C=CC=CC=2)CC1 UXRQPYBOLVQYQD-UHFFFAOYSA-N 0.000 claims description 2
SQTBYARBJNHGQJ-UHFFFAOYSA-N 2-[[4-(4-phenylpiperazin-1-yl)phenyl]sulfonylamino]acetic acid Chemical compound C1=CC(S(=O)(=O)NCC(=O)O)=CC=C1N1CCN(C=2C=CC=CC=2)CC1 SQTBYARBJNHGQJ-UHFFFAOYSA-N 0.000 claims description 2
RDUOXXVFDHHAPP-UHFFFAOYSA-N 3-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]propanoic acid Chemical compound C1=CC(S(=O)(=O)NCCC(=O)O)=CC=C1N1CCC(C=2C=CC=CC=2)CC1 RDUOXXVFDHHAPP-UHFFFAOYSA-N 0.000 claims description 2
YIBZPVVKWIHFLM-UHFFFAOYSA-N 5-phenyl-2-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]pentanoic acid Chemical compound C=1C=C(N2CCC(CC2)C=2C=CC=CC=2)C=CC=1S(=O)(=O)NC(C(=O)O)CCCC1=CC=CC=C1 YIBZPVVKWIHFLM-UHFFFAOYSA-N 0.000 claims description 2
XTZSTNYJRISMQA-UHFFFAOYSA-N n-hydroxy-2-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]acetamide Chemical compound C1=CC(S(=O)(=O)NCC(=O)NO)=CC=C1N1CCC(C=2C=CC=CC=2)CC1 XTZSTNYJRISMQA-UHFFFAOYSA-N 0.000 claims description 2
WZYVYOMZRLPZKB-JFRIYMKVSA-M sodium;(2r)-2-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]-3-tritylsulfanylpropanoate Chemical compound [Na+].C([C@@H](C(=O)[O-])NS(=O)(=O)C=1C=CC(=CC=1)N1CCC(CC1)C=1C=CC=CC=1)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WZYVYOMZRLPZKB-JFRIYMKVSA-M 0.000 claims description 2
230000002265 prevention Effects 0.000 claims 2
ADRXVXDGDFNWTL-JIDHJSLPSA-N (2s)-2-[[4-[4-(3-hydroxyphenyl)piperazin-1-yl]phenyl]sulfonylamino]-3-phenylpropanoic acid;hydrobromide Chemical compound Br.C([C@@H](C(=O)O)NS(=O)(=O)C=1C=CC(=CC=1)N1CCN(CC1)C=1C=C(O)C=CC=1)C1=CC=CC=C1 ADRXVXDGDFNWTL-JIDHJSLPSA-N 0.000 claims 1
SMCUDZWBQOPQEA-SANMLTNESA-N (2s)-4-phenyl-2-[[4-(4-phenylpiperidin-1-yl)phenyl]sulfonylamino]butanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=CC(=CC=1)N1CCC(CC1)C=1C=CC=CC=1)CC1=CC=CC=C1 SMCUDZWBQOPQEA-SANMLTNESA-N 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
230000007505 plaque formation Effects 0.000 claims 1
238000000034 method Methods 0.000 abstract description 18
206010019280 Heart failures Diseases 0.000 abstract description 10
206010064996 Ulcerative keratitis Diseases 0.000 abstract description 5
102000013382 Gelatinases Human genes 0.000 abstract description 4
108010026132 Gelatinases Proteins 0.000 abstract description 4
230000005747 tumor angiogenesis Effects 0.000 abstract description 4
206010027476 Metastases Diseases 0.000 abstract description 3
230000001419 dependent effect Effects 0.000 abstract description 2
230000009401 metastasis Effects 0.000 abstract 1
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
239000000203 mixture Substances 0.000 description 41
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 37
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
239000007787 solid Substances 0.000 description 32
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
239000002253 acid Substances 0.000 description 25
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 23
WZHRJGWXUCLILI-UHFFFAOYSA-N sulfonylcarbamic acid Chemical compound OC(=O)N=S(=O)=O WZHRJGWXUCLILI-UHFFFAOYSA-N 0.000 description 23
239000002904 solvent Substances 0.000 description 22
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
239000002585 base Substances 0.000 description 17
239000000243 solution Substances 0.000 description 15
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
229910000029 sodium carbonate Inorganic materials 0.000 description 12
ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 11
239000000843 powder Substances 0.000 description 11
239000000741 silica gel Substances 0.000 description 11
229910002027 silica gel Inorganic materials 0.000 description 11
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
150000001412 amines Chemical class 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
235000019260 propionic acid Nutrition 0.000 description 10
239000004480 active ingredient Substances 0.000 description 9
239000002775 capsule Substances 0.000 description 9
150000002148 esters Chemical class 0.000 description 9
UPZJLQCUYUTZIE-UHFFFAOYSA-N hydron;4-phenylpiperidine;chloride Chemical compound Cl.C1CNCCC1C1=CC=CC=C1 UPZJLQCUYUTZIE-UHFFFAOYSA-N 0.000 description 9
239000000047 product Substances 0.000 description 9
239000000725 suspension Substances 0.000 description 9
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
MSQACBWWAIBWIC-UHFFFAOYSA-N hydron;piperazine;chloride Chemical compound Cl.C1CNCCN1 MSQACBWWAIBWIC-UHFFFAOYSA-N 0.000 description 8
RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
150000007513 acids Chemical class 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
229910052736 halogen Inorganic materials 0.000 description 7
150000002367 halogens Chemical class 0.000 description 7
239000010410 layer Substances 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
239000012044 organic layer Substances 0.000 description 6
229910000027 potassium carbonate Inorganic materials 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
108091007196 stromelysin Proteins 0.000 description 6
239000003826 tablet Substances 0.000 description 6
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 5
238000005160 1H NMR spectroscopy Methods 0.000 description 5
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
230000003197 catalytic effect Effects 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 5
210000002744 extracellular matrix Anatomy 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
239000007788 liquid Substances 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
102000029816 Collagenase Human genes 0.000 description 4
108060005980 Collagenase Proteins 0.000 description 4
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
239000011260 aqueous acid Substances 0.000 description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
229910052794 bromium Inorganic materials 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000000460 chlorine Substances 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
229960002424 collagenase Drugs 0.000 description 4
239000007822 coupling agent Substances 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
239000012458 free base Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
239000000463 material Substances 0.000 description 4
230000005012 migration Effects 0.000 description 4
238000013508 migration Methods 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
XAEAUZAGDOXYIE-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonylamino]acetic acid Chemical compound OC(=O)CNS(=O)(=O)C1=CC=C(F)C=C1 XAEAUZAGDOXYIE-UHFFFAOYSA-N 0.000 description 3
FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 3
102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 3
108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
HKPBBSIBGJAOMU-RGMNGODLSA-M [Na+].FC1=CC=C(C=C1)S(=O)(=O)N[C@H](C(=O)[O-])C Chemical compound [Na+].FC1=CC=C(C=C1)S(=O)(=O)N[C@H](C(=O)[O-])C HKPBBSIBGJAOMU-RGMNGODLSA-M 0.000 description 3
150000001299 aldehydes Chemical class 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000013355 food flavoring agent Nutrition 0.000 description 3
239000012634 fragment Substances 0.000 description 3
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
210000002510 keratinocyte Anatomy 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
150000004885 piperazines Chemical class 0.000 description 3
150000003053 piperidines Chemical class 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000012258 stirred mixture Substances 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
239000003039 volatile agent Substances 0.000 description 3
QBRGIJYBQSSWND-NSHDSACASA-N (2s)-2-[(4-fluorophenyl)sulfonylamino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NS(=O)(=O)C1=CC=C(F)C=C1 QBRGIJYBQSSWND-NSHDSACASA-N 0.000 description 2
YXFMLDCNGMKAPW-UHFFFAOYSA-N 2-[(4-fluorophenyl)sulfonylamino]-5-phenylpentanoic acid Chemical compound C=1C=C(F)C=CC=1S(=O)(=O)NC(C(=O)O)CCCC1=CC=CC=C1 YXFMLDCNGMKAPW-UHFFFAOYSA-N 0.000 description 2
XOQZTHUXZWQXOK-UHFFFAOYSA-N 2-azaniumyl-5-phenylpentanoate Chemical compound OC(=O)C(N)CCCC1=CC=CC=C1 XOQZTHUXZWQXOK-UHFFFAOYSA-N 0.000 description 2
KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
208000025494 Aortic disease Diseases 0.000 description 2
208000006029 Cardiomegaly Diseases 0.000 description 2
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
108010076497 Matrix Metalloproteinase 10 Proteins 0.000 description 2
102000005741 Metalloproteases Human genes 0.000 description 2
108010006035 Metalloproteases Proteins 0.000 description 2
102000056189 Neutrophil collagenases Human genes 0.000 description 2
101001013135 Rattus norvegicus Interstitial collagenase Proteins 0.000 description 2
102100028848 Stromelysin-2 Human genes 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000003513 alkali Substances 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
150000001350 alkyl halides Chemical class 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
238000010171 animal model Methods 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000010531 catalytic reduction reaction Methods 0.000 description 2
230000004709 cell invasion Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
239000003086 colorant Substances 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
201000002491 encephalomyelitis Diseases 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
210000002615 epidermis Anatomy 0.000 description 2
MVUSMEFJCYFJLU-UHFFFAOYSA-N ethyl 2-(2-methylpropylamino)acetate;hydrochloride Chemical compound Cl.CCOC(=O)CNCC(C)C MVUSMEFJCYFJLU-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
238000002844 melting Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
AEKHNNJSMVVESS-UHFFFAOYSA-N o-trimethylsilylhydroxylamine Chemical compound C[Si](C)(C)ON AEKHNNJSMVVESS-UHFFFAOYSA-N 0.000 description 2
230000003239 periodontal effect Effects 0.000 description 2
YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000002798 polar solvent Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000007634 remodeling Methods 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000004576 sand Substances 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
210000001179 synovial fluid Anatomy 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
ZYZHMSJNPCYUTB-CYBMUJFWSA-N (1r)-n-benzyl-1-phenylethanamine Chemical compound N([C@H](C)C=1C=CC=CC=1)CC1=CC=CC=C1 ZYZHMSJNPCYUTB-CYBMUJFWSA-N 0.000 description 1
ZYZHMSJNPCYUTB-ZDUSSCGKSA-N (1s)-n-benzyl-1-phenylethanamine Chemical compound N([C@@H](C)C=1C=CC=CC=1)CC1=CC=CC=C1 ZYZHMSJNPCYUTB-ZDUSSCGKSA-N 0.000 description 1
JRSXZZNEKZTTJP-CQSZACIVSA-N (2r)-2-[(4-fluorophenyl)sulfonylamino]-3-phenylpropanoic acid Chemical compound C([C@H](C(=O)O)NS(=O)(=O)C=1C=CC(F)=CC=1)C1=CC=CC=C1 JRSXZZNEKZTTJP-CQSZACIVSA-N 0.000 description 1
QBRGIJYBQSSWND-LLVKDONJSA-N (2r)-2-[(4-fluorophenyl)sulfonylamino]-4-methylpentanoic acid Chemical compound CC(C)C[C@H](C(O)=O)NS(=O)(=O)C1=CC=C(F)C=C1 QBRGIJYBQSSWND-LLVKDONJSA-N 0.000 description 1
LEMVXFLDSISVNM-INIZCTEOSA-N (2s)-2-[(4-fluorophenyl)sulfonylamino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LEMVXFLDSISVNM-INIZCTEOSA-N 0.000 description 1
SGPYWFVFEUQLDL-NRFANRHFSA-N (2s)-2-[(4-fluorophenyl)sulfonylamino]-3-(4-phenylmethoxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=CC(F)=CC=1)C(C=C1)=CC=C1OCC1=CC=CC=C1 SGPYWFVFEUQLDL-NRFANRHFSA-N 0.000 description 1
SRIFDSHVNNIYLB-JIDHJSLPSA-N (2s)-2-[[4-[4-(4-chlorophenyl)piperazin-1-yl]phenyl]sulfonylamino]-3-phenylpropanoic acid;hydrochloride Chemical compound Cl.C([C@@H](C(=O)O)NS(=O)(=O)C=1C=CC(=CC=1)N1CCN(CC1)C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 SRIFDSHVNNIYLB-JIDHJSLPSA-N 0.000 description 1
PGXLAZACGSXLAI-VWLOTQADSA-N (2s)-2-[[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]sulfonylamino]-3-phenylpropanoic acid Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(=CC=2)S(=O)(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CC1 PGXLAZACGSXLAI-VWLOTQADSA-N 0.000 description 1
PZIBVWUXWNYTNL-UHFFFAOYSA-N 1-(3-methoxyphenyl)piperazine Chemical compound COC1=CC=CC(N2CCNCC2)=C1 PZIBVWUXWNYTNL-UHFFFAOYSA-N 0.000 description 1
MMXANKLJIHSIQH-UHFFFAOYSA-N 1-(4-methoxyphenyl)piperazine-1,4-diium;dichloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1N1CCNCC1 MMXANKLJIHSIQH-UHFFFAOYSA-N 0.000 description 1
SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
NATYAPACRIEJOH-UHFFFAOYSA-N 2-acetamido-5-phenylpentanoic acid Chemical compound CC(=O)NC(C(O)=O)CCCC1=CC=CC=C1 NATYAPACRIEJOH-UHFFFAOYSA-N 0.000 description 1
YMDZDFSUDFLGMX-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)ethanamine;hydron;chloride Chemical compound [Cl-].ClCC[NH2+]CCCl YMDZDFSUDFLGMX-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
NFNLMAWRYHNLPI-UHFFFAOYSA-N 3-phenylpropanoic acid hydrobromide Chemical compound Br.C1(=CC=CC=C1)CCC(=O)O NFNLMAWRYHNLPI-UHFFFAOYSA-N 0.000 description 1
ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 description 1
UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
244000144730 Amygdalus persica Species 0.000 description 1
206010003162 Arterial injury Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
VHLXMXQFTPFHDH-BTQNPOSSSA-N C(C1=CC=CC=C1)N[C@@H](C1=CC=CC=C1)C.[Li] Chemical compound C(C1=CC=CC=C1)N[C@@H](C1=CC=CC=C1)C.[Li] VHLXMXQFTPFHDH-BTQNPOSSSA-N 0.000 description 1
KUFJUSDUDBSDAM-FFAASGSZSA-L C1=CC=C(C=C1)C[C@H](C(=O)[O-])NS(=O)(=O)C2=CC=C(C=C2)F.C1=CC=C(C=C1)C[C@H](C(=O)[O-])NS(=O)(=O)C2=CC=C(C=C2)F.[Na+].[Na+] Chemical compound C1=CC=C(C=C1)C[C@H](C(=O)[O-])NS(=O)(=O)C2=CC=C(C=C2)F.C1=CC=C(C=C1)C[C@H](C(=O)[O-])NS(=O)(=O)C2=CC=C(C=C2)F.[Na+].[Na+] KUFJUSDUDBSDAM-FFAASGSZSA-L 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010011091 Coronary artery thrombosis Diseases 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
244000166102 Eucalyptus leucoxylon Species 0.000 description 1
235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
NGPWGJQBFLBVQM-FYZYNONXSA-N FC(C(=O)O)(F)F.SC[C@@H](C(=O)O)NS(=O)(=O)C1=CC=C(C=C1)N1CCC(CC1)C1=CC=CC=C1 Chemical compound FC(C(=O)O)(F)F.SC[C@@H](C(=O)O)NS(=O)(=O)C1=CC=C(C=C1)N1CCC(CC1)C1=CC=CC=C1 NGPWGJQBFLBVQM-FYZYNONXSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010060820 Joint injury Diseases 0.000 description 1
208000016593 Knee injury Diseases 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229940124761 MMP inhibitor Drugs 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
102000004318 Matrilysin Human genes 0.000 description 1
108090000855 Matrilysin Proteins 0.000 description 1
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
102000011722 Matrix Metalloproteinase 13 Human genes 0.000 description 1
108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
108010088571 Membrane-Associated Matrix Metalloproteinases Proteins 0.000 description 1
102000008887 Membrane-Associated Matrix Metalloproteinases Human genes 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
208000034827 Neointima Diseases 0.000 description 1
108030001564 Neutrophil collagenases Proteins 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
KAFHLONDOVSENM-HNNXBMFYSA-N O-Benzyl-L-tyrosine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OCC1=CC=CC=C1 KAFHLONDOVSENM-HNNXBMFYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
235000006040 Prunus persica var persica Nutrition 0.000 description 1
241000219061 Rheum Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
102100028847 Stromelysin-3 Human genes 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 1
102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
208000019269 advanced heart failure Diseases 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
206010002906 aortic stenosis Diseases 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
159000000032 aromatic acids Chemical class 0.000 description 1
210000001188 articular cartilage Anatomy 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
230000000963 caseinolytic effect Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
230000003366 colagenolytic effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
208000002528 coronary thrombosis Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
FDSGHYHRLSWSLQ-UHFFFAOYSA-N dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O FDSGHYHRLSWSLQ-UHFFFAOYSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000005530 etching Methods 0.000 description 1
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
210000000497 foam cell Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000000477 gelanolytic effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
210000004195 gingiva Anatomy 0.000 description 1
208000024693 gingival disease Diseases 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000004217 heart function Effects 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
OHZZTXYKLXZFSZ-UHFFFAOYSA-I manganese(3+) 5,10,15-tris(1-methylpyridin-1-ium-4-yl)-20-(1-methylpyridin-4-ylidene)porphyrin-22-ide pentachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3].C1=CN(C)C=CC1=C1C(C=C2)=NC2=C(C=2C=C[N+](C)=CC=2)C([N-]2)=CC=C2C(C=2C=C[N+](C)=CC=2)=C(C=C2)N=C2C(C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 OHZZTXYKLXZFSZ-UHFFFAOYSA-I 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000008384 membrane barrier Effects 0.000 description 1
125000005341 metaphosphate group Chemical group 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
SIGOIUCRXKUEIG-UHFFFAOYSA-N methyl 2-dimethoxyphosphorylacetate Chemical compound COC(=O)CP(=O)(OC)OC SIGOIUCRXKUEIG-UHFFFAOYSA-N 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
235000021096 natural sweeteners Nutrition 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
SSUCKKNRCOFUPT-UHFFFAOYSA-N o-[tert-butyl(dimethyl)silyl]hydroxylamine Chemical compound CC(C)(C)[Si](C)(C)ON SSUCKKNRCOFUPT-UHFFFAOYSA-N 0.000 description 1
XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003349 osteoarthritic effect Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940049953 phenylacetate Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical class NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229940116351 sebacate Drugs 0.000 description 1
CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000015590 smooth muscle cell migration Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000007704 transition Effects 0.000 description 1
210000004231 tunica media Anatomy 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
238000007805 zymography Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Dental Preparations (AREA)

NO19982223A 1995-11-17 1998-05-15 Sulfonamid-inhibitorer av matriks-metalloproteinaser, anvendelse av disse og farmasöytiske preparater inneholdende dem NO310231B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US737295P	1995-11-17	1995-11-17
PCT/US1996/016761 WO1997019068A1 (fr)	1995-11-17	1996-10-18	Inhibiteurs de metalloprotineases matricielles a base de sulfamide

Publications (3)

Publication Number	Publication Date
NO982223L NO982223L (no)	1998-05-15
NO982223D0 NO982223D0 (no)	1998-05-15
NO310231B1 true NO310231B1 (no)	2001-06-11

Family

ID=21725784

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19982223A NO310231B1 (no)	1995-11-17	1998-05-15	Sulfonamid-inhibitorer av matriks-metalloproteinaser, anvendelse av disse og farmasöytiske preparater inneholdende dem

Country Status (20)

Country	Link
US (3)	US5977141A (fr)
EP (1)	EP0874836B1 (fr)
JP (1)	JP2000514779A (fr)
AT (1)	ATE225779T1 (fr)
AU (1)	AU727569B2 (fr)
BG (1)	BG63967B1 (fr)
BR (1)	BR9611487A (fr)
CZ (1)	CZ291659B6 (fr)
DE (1)	DE69624262T2 (fr)
DK (1)	DK0874836T3 (fr)
ES (1)	ES2184893T3 (fr)
HU (1)	HUP9902083A3 (fr)
IL (1)	IL123901A (fr)
NO (1)	NO310231B1 (fr)
NZ (1)	NZ321293A (fr)
PL (1)	PL326700A1 (fr)
PT (1)	PT874836E (fr)
SK (1)	SK282833B6 (fr)
WO (1)	WO1997019068A1 (fr)
ZA (1)	ZA969584B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6613804B2 (en)	1993-05-20	2003-09-02	Encysive Pharmaceuticals, Inc.	Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6500948B1 (en)	1995-12-08	2002-12-31	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
ES2233275T3 (es) *	1995-12-08	2005-06-16	Agouron Pharmaceuticals, Inc.	Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
US6747027B1 (en) *	1996-07-22	2004-06-08	Pharmacia Corporation	Thiol sulfonamide metalloprotease inhibitors
US6624177B1 (en)	1996-09-04	2003-09-23	Warner-Lambert Company	Matrix metalloproteinase inhibitors and their therapeutic uses
AU735013B2 (en) *	1996-09-04	2001-06-28	Warner-Lambert Company	Matrix metalloproteinase inhibitors and their therapeutic uses
JP2002514180A (ja)	1996-09-04	2002-05-14	ワーナー―ランバート・コンパニー	マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法
US6228869B1 (en)	1996-10-16	2001-05-08	American Cyanamid Company	Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6548524B2 (en)	1996-10-16	2003-04-15	American Cyanamid Company	Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5929097A (en) *	1996-10-16	1999-07-27	American Cyanamid Company	Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5977408A (en) *	1996-10-16	1999-11-02	American Cyanamid Company	Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5962481A (en) *	1996-10-16	1999-10-05	American Cyanamid Company	Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6174915B1 (en)	1997-03-25	2001-01-16	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) *	1996-10-24	1999-12-28	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
KR20000057444A (ko) *	1996-12-09	2000-09-15	로즈 암스트롱, 크리스틴 에이. 트러트웨인	심기능부전 및 심실확장의 치료 및 예방 방법
SI0946166T1 (en) *	1996-12-17	2004-06-30	Warner-Lambert Company Llc	Use of matrix metalloproteinase inhibitors for promoting wound healing
ES2212142T3 (es)	1996-12-17	2004-07-16	Warner-Lambert Company Llc	Uso de inhibidores de metaloproteinasas de la matriz para promover la curacion de heridas.
US5985900A (en) *	1997-04-01	1999-11-16	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP3455233B2 (ja)	1997-04-28	2003-10-14	テキサス・バイオテクノロジー・コーポレイシヨン	エンドテリン介在障害治療用のスルホンアミド類
DE19719621A1 (de) *	1997-05-09	1998-11-12	Hoechst Ag	Sulfonylaminocarbonsäuren
PT877019E (pt) *	1997-05-09	2002-05-31	Hoechst Ag	Acidos diaminocarboxilicos substituidos
US6410580B1 (en)	1998-02-04	2002-06-25	Novartis Ag	Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
JP4750272B2 (ja)	1998-02-04	2011-08-17	ノバルティスアーゲー	マトリックス分解メタロプロテイナーゼを阻害するスルホニルアミノ誘導体
AU5647099A (en) *	1998-09-11	2000-04-03	Shionogi & Co., Ltd.	Remedal or preventive agent for congestive heart failure
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6762178B2 (en)	1999-01-27	2004-07-13	Wyeth Holdings Corporation	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en)	1999-01-27	2005-09-20	Wyeth Holdings Corporation	Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6326516B1 (en)	1999-01-27	2001-12-04	American Cyanamid Company	Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en)	1999-01-27	2002-01-22	American Cyanamid Company	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6358980B1 (en)	1999-01-27	2002-03-19	American Cyanamid Company	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6313123B1 (en)	1999-01-27	2001-11-06	American Cyanamid Company	Acetylenic sulfonamide thiol tace inhibitors
US6200996B1 (en)	1999-01-27	2001-03-13	American Cyanamid Company	Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6753337B2 (en)	1999-01-27	2004-06-22	Wyeth Holdings Corporation	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6277885B1 (en)	1999-01-27	2001-08-21	American Cyanamid Company	Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6225311B1 (en)	1999-01-27	2001-05-01	American Cyanamid Company	Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6465508B1 (en)	2000-02-25	2002-10-15	Wyeth	Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
US20030105144A1 (en)	2001-04-17	2003-06-05	Ping Gao	Stabilized oral pharmaceutical composition
BR0213736A (pt)	2001-11-01	2004-10-19	Wyeth Corp	ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
CA2471099C (fr) *	2001-12-20	2011-04-12	Bristol-Myers Squibb Company	Derives d'.alpha.-(n-sulphonamido)acetamide en tant qu'inhibiteurs de .beta.-amyloide
US6864478B2 (en) *	2002-04-22	2005-03-08	Visx, Incorporation	Beam position monitoring for laser eye surgery
US7199155B2 (en)	2002-12-23	2007-04-03	Wyeth Holdings Corporation	Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
AU2003300076C1 (en)	2002-12-30	2010-03-04	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
US7537774B2 (en) *	2005-12-23	2009-05-26	Orion Therapeautics, Llc	Therapeutic formulation
WO2007102392A1 (fr) *	2006-03-03	2007-09-13	Shionogi & Co., Ltd.	Inhibiteur selectif de mmp-13
WO2008053913A1 (fr) *	2006-11-02	2008-05-08	Shionogi & Co., Ltd.	Dérivé de sulfonylurée capable d'inhiber sélectivement mmp-13
US8093276B2 (en) *	2007-10-31	2012-01-10	Bristol-Myers Squibb Company	Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) *	2007-10-31	2011-12-27	Bristol-Myers Squibb Company	Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
WO2009137657A1 (fr) *	2008-05-08	2009-11-12	Bristol-Myers Squibb Company	Dérivés du 2-arylglycinamide
US8044077B2 (en) *	2009-03-19	2011-10-25	Bristol-Myers Squibb Company	Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) *	2009-03-20	2011-07-12	Bristol-Myers Squibb Company	Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) *	2009-03-20	2011-03-24	Bristol-Myers Squibb Company	Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US8252821B2 (en) *	2009-04-14	2012-08-28	Bristol-Myers Squibb Company	Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) *	2009-04-14	2010-12-16	Bristol Myers Squibb Co	Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0100158A3 (fr) *	1982-07-28	1985-03-27	The Upjohn Company	Hétéroalkysylalkanoles 3-pyridinyliques, leurs acides alkanoiques et leurs esters
DE3330603A1 (de) *	1983-08-25	1985-03-21	Hoechst Ag, 6230 Frankfurt	Neue 2-amino-alkenylsulfonylharnstoffe
GB8609630D0 (en) *	1986-04-19	1986-05-21	Pfizer Ltd	Anti-arrhythmia agents
JPH08504194A (ja) *	1992-12-01	1996-05-07	メルクエンドカンパニーインコーポレーテッド	フィブリノーゲンレセプターアンタゴニスト
CA2110524A1 (fr) *	1992-12-10	1994-06-11	Gerald Burr Grindey	Compositions antitumorales et methodes de traitement
US5552419A (en) *	1993-01-06	1996-09-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) *	1993-01-06	1996-04-09	Ciba-Geigy Corporation	Arylsufonamido-substituted hydroxamic acids
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
AU692438B2 (en) *	1993-03-29	1998-06-11	Astrazeneca Ab	Heterocyclic derivatives as platelet aggregation inhibitors
IT1266582B1 (it) *	1993-07-30	1997-01-09	Recordati Chem Pharm	Derivati (di)azacicloesanici e diazacicloeptanici
PT822186E (pt) *	1994-01-20	2000-08-31	British Biotech Pharm	L-tert-leucina-2-piridilamida
US5514716A (en) *	1994-02-25	1996-05-07	Sterling Winthrop, Inc.	Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
US5817822A (en) *	1994-06-24	1998-10-06	Novartis Corporation	Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
US5919940A (en) *	1995-01-20	1999-07-06	British Biotech Pharmaceuticals Limited	Metalloproteinase inhibitors
KR20000057444A (ko) *	1996-12-09	2000-09-15	로즈 암스트롱, 크리스틴 에이. 트러트웨인	심기능부전 및 심실확장의 치료 및 예방 방법
ES2212142T3 (es) *	1996-12-17	2004-07-16	Warner-Lambert Company Llc	Uso de inhibidores de metaloproteinasas de la matriz para promover la curacion de heridas.

1996
- 1996-10-18 SK SK641-98A patent/SK282833B6/sk unknown
- 1996-10-18 ES ES96936718T patent/ES2184893T3/es not_active Expired - Lifetime
- 1996-10-18 PL PL96326700A patent/PL326700A1/xx unknown
- 1996-10-18 NZ NZ321293A patent/NZ321293A/en unknown
- 1996-10-18 PT PT96936718T patent/PT874836E/pt unknown
- 1996-10-18 US US09/068,726 patent/US5977141A/en not_active Expired - Fee Related
- 1996-10-18 AT AT96936718T patent/ATE225779T1/de not_active IP Right Cessation
- 1996-10-18 DE DE69624262T patent/DE69624262T2/de not_active Expired - Fee Related
- 1996-10-18 IL IL12390196A patent/IL123901A/xx not_active IP Right Cessation
- 1996-10-18 DK DK96936718T patent/DK0874836T3/da active
- 1996-10-18 HU HU9902083A patent/HUP9902083A3/hu unknown
- 1996-10-18 EP EP96936718A patent/EP0874836B1/fr not_active Expired - Lifetime
- 1996-10-18 WO PCT/US1996/016761 patent/WO1997019068A1/fr not_active Ceased
- 1996-10-18 CZ CZ19981467A patent/CZ291659B6/cs not_active IP Right Cessation
- 1996-10-18 JP JP09519715A patent/JP2000514779A/ja not_active Abandoned
- 1996-10-18 AU AU74641/96A patent/AU727569B2/en not_active Ceased
- 1996-10-18 BR BR9611487A patent/BR9611487A/pt not_active IP Right Cessation
- 1996-11-14 ZA ZA969584A patent/ZA969584B/xx unknown
1998
- 1998-05-13 BG BG102448A patent/BG63967B1/bg unknown
- 1998-05-15 NO NO19982223A patent/NO310231B1/no not_active IP Right Cessation
1999
- 1999-10-05 US US09/412,707 patent/US6153612A/en not_active Expired - Fee Related
2000
- 2000-06-22 US US09/599,306 patent/US6297247B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO982223L (no)	1998-05-15
SK64198A3 (en)	1998-10-07
EP0874836A1 (fr)	1998-11-04
JP2000514779A (ja)	2000-11-07
AU7464196A (en)	1997-06-11
SK282833B6 (sk)	2002-12-03
NZ321293A (en)	2001-04-27
WO1997019068A1 (fr)	1997-05-29
PL326700A1 (en)	1998-10-26
BR9611487A (pt)	1999-01-19
US5977141A (en)	1999-11-02
CZ146798A3 (cs)	1998-08-12
BG102448A (en)	1999-08-31
CZ291659B6 (cs)	2003-04-16
IL123901A0 (en)	1998-10-30
AU727569B2 (en)	2000-12-14
HUP9902083A3 (en)	2000-06-28
NO982223D0 (no)	1998-05-15
ZA969584B (en)	1997-06-02
DK0874836T3 (da)	2003-02-10
DE69624262T2 (de)	2003-09-11
ATE225779T1 (de)	2002-10-15
ES2184893T3 (es)	2003-04-16
BG63967B1 (bg)	2003-08-29
IL123901A (en)	2003-06-24
HUP9902083A2 (hu)	1999-10-28
US6153612A (en)	2000-11-28
PT874836E (pt)	2003-02-28
EP0874836B1 (fr)	2002-10-09
US6297247B1 (en)	2001-10-02
DE69624262D1 (de)	2002-11-14

Legal Events

Date	Code	Title	Description
2005-06-20	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO310231B1 (no)	2001-06-11	Sulfonamid-inhibitorer av matriks-metalloproteinaser, anvendelse av disse og farmasöytiske preparater inneholdende dem
JP4776778B2 (ja)	2011-09-21	アリールピペラジン類および金属プロテイナーゼ阻害剤（ｍｍｐ）としてのそれらの用途
US6008220A (en)	1999-12-28	Aromatic keto-acids and their derivatives as inhibitors of matrix metalloproteinases
US6117869A (en)	2000-09-12	Compounds for and methods of inhibiting matrix metalloproteinases
JP2003525203A (ja)	2003-08-26	ヒドロキサムおよびカルボン酸誘導体
US6677355B1 (en)	2004-01-13	Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors
JP2002542228A (ja)	2002-12-10	Ｍｍｐ阻害剤
KR20020005769A (ko)	2002-01-17	메탈로프로테이나제의 억제제
KR20020079882A (ko)	2002-10-19	아릴피페라진 및 아릴피페리딘 및 금속단백질분해효소억제제로서의 그의 용도
CA2233560C (fr)	2005-12-20	Inhibiteurs de metalloprotineases matricielles a base de sulfamide
US6624177B1 (en)	2003-09-23	Matrix metalloproteinase inhibitors and their therapeutic uses
MXPA98003315A (en)	1998-11-16	Queto aromatic acids and their derivatives as inhibitors of metaloproteinases mat
US20060142363A1 (en)	2006-06-29	Imidazolidinedione analogs useful as anticoagulants and antithrombotics
CA2236096A1 (fr)	1997-07-03	Ceto-acides aromatiques et leurs derives comme inhibiteurs de metalloproteinases matricielles
MXPA98009871A (en)	1999-04-27	Matrix metalloproteinase inhibitors and their therapeutic uses
MXPA98009929A (en)	1999-04-27	Compounds for and a method of inhibiting matrix metalloproteinases